down arrow

Bristol Myers Squibb Co.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US1101221083
USD
51.95
0.99 (1.94%)

Dec 04

NYS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

50.2352.08

52 Week

42.5263.33
Valuation
Technical
Day's Volume

CASH

5.86 M

Shareholding (Mar 2025)

FII

19.79%

Held by 593 FIIs

DII

45.3%

Held by 209 DIIs

Promoter

0.10%

How big is Bristol Myers Squibb Co.?

22-Jun-2025

As of Jun 18, Bristol Myers Squibb Co. has a market capitalization of $129.32 billion, with recent net sales of $47.64 billion and a net profit of $5.44 billion.

Market Cap: As of Jun 18, Bristol Myers Squibb Co. has a market capitalization of 129,319.56 million, classifying it as a Large Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Bristol Myers Squibb Co. reported net sales of 47,636.00 million and a net profit of 5,437.00 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 16,335.00 million and total assets of 92,603.00 million.

Read More

What does Bristol Myers Squibb Co. do?

22-Jun-2025

Bristol Myers Squibb Co. is a large-cap biopharmaceutical company involved in the discovery, development, and sale of pharmaceutical products. As of March 2025, it reported net sales of $11.2 billion and a net profit of $2.5 billion.

Overview:<BR>Bristol Myers Squibb Co. is engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products within the Pharmaceuticals & Biotechnology industry, classified as a large-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 11,201 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 2,462 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 129,319.56 Million (Large Cap)<BR><BR>Key Metrics:<BR>P/E: 15.00 <BR>Dividend Yield: 78.83% <BR>Debt Equity: 2.19 <BR>Return on Equity: 49.65% <BR>Price to Book: 7.44<BR><BR>Contact Details:<BR>Address: 430 E 29th St Fl 14, NEW YORK NY: 10016-8367 <BR>Tel: ['1 212 5464000', '1 609 2527509'] <BR>Fax: 1 302 6555049 <BR>Website: https://www.bms.com/

Read More

Who are in the management team of Bristol Myers Squibb Co.?

22-Jun-2025

As of March 2022, Bristol Myers Squibb Co.'s management team includes Dr. Giovanni Caforio as Chairman and CEO, and Dr. Vicki Sato as Lead Independent Director, along with independent directors Peter Arduini, Robert Bertolini, Michael Bonney, and Matthew Emmens.

As of March 2022, the management team of Bristol Myers Squibb Co. includes Dr. Giovanni Caforio, who serves as the Chairman of the Board and Chief Executive Officer. Additionally, Dr. Vicki Sato holds the position of Lead Independent Director. The board also features several independent directors: Mr. Peter Arduini, Mr. Robert Bertolini, Mr. Michael Bonney, and Mr. Matthew Emmens.

Read More

Is Bristol Myers Squibb Co. overvalued or undervalued?

20-Sep-2025

As of July 31, 2025, Bristol Myers Squibb Co. is considered very attractive due to its undervalued P/E ratio of 15, favorable EV to EBITDA ratio of 9.01, and high ROE of 49.65%, despite underperforming the S&P 500 with a year-to-date return of -19.38%.

As of 31 July 2025, the valuation grade for Bristol Myers Squibb Co. has moved from attractive to very attractive, indicating a positive shift in its perceived value. The company appears to be undervalued, particularly when considering its P/E ratio of 15, which is significantly lower than the industry average, and its EV to EBITDA ratio of 9.01, which also suggests a favorable valuation relative to earnings before interest, taxes, depreciation, and amortization. Additionally, the company boasts a high ROE of 49.65%, reflecting strong profitability.<BR><BR>In comparison to its peers, Bristol Myers Squibb Co. has a P/E ratio of 14.33, which is lower than Eli Lilly & Co. at 40.89 and Johnson & Johnson at 26.18, reinforcing its undervaluation. The company’s EV to EBITDA ratio of 9.01 is also more attractive than AbbVie, Inc. at 16.51. Despite the positive valuation metrics, Bristol Myers Squibb has underperformed the S&P 500 in recent periods, with a year-to-date return of -19.38% compared to the S&P 500's 12.22%, suggesting that the market may not fully recognize its value yet.

Read More

Is Bristol Myers Squibb Co. technically bullish or bearish?

05-Nov-2025

As of October 31, 2025, Bristol Myers Squibb Co. shows a mildly bearish technical trend with mixed signals across indicators, underperforming the S&P 500 year-to-date by -19.40% compared to its 16.30% gain.

As of 31 October 2025, the technical trend for Bristol Myers Squibb Co. has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD remains bearish. The daily moving averages are mildly bearish, and the KST is bearish on both weekly and monthly time frames. The Bollinger Bands show a sideways trend weekly and bearish monthly. Dow Theory suggests a mildly bullish outlook on the weekly basis, but no trend on the monthly.<BR><BR>In terms of performance, Bristol Myers Squibb has underperformed the S&P 500 across multiple periods, with a year-to-date return of -19.40% compared to the S&P 500's 16.30%, and a one-year return of -16.07% versus 19.89%. Overall, the current technical stance is mildly bearish, with mixed signals across different indicators.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Healthy long term growth as Net Sales has grown by an annual rate of 6.47% and Operating profit at 23.31%

 
2

The company has declared positive results in Mar'2025 after 4 consecutive negative quarters

3

With ROCE of 19.69%, it has a fair valuation with a 3.08 Enterprise value to Capital Employed

4

Consistent Underperformance against the benchmark over the last 3 years

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 127,940 Million (Large Cap)

stock-summary
P/E

15.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

80.34%

stock-summary
Debt Equity

2.05

stock-summary
Return on Equity

51.19%

stock-summary
Price to Book

7.34

Revenue and Profits:
Net Sales:
12,269 Million
(Quarterly Results - Jun 2025)
Net Profit:
1,313 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
11.27%
0%
11.27%
6 Months
8.34%
0%
8.34%
1 Year
-11.0%
0%
-11.0%
2 Years
3.94%
0%
3.94%
3 Years
-35.97%
0%
-35.97%
4 Years
-7.76%
0%
-7.76%
5 Years
-16.63%
0%
-16.63%

Bristol Myers Squibb Co. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Bristol Myers Squibb Co. technically bullish or bearish?

As of 31 October 2025, the technical trend for Bristol Myers Squibb Co. has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD remains bearish. The daily moving averages are mildly bearish, and the KST is bearish on both weekly and monthly time frames. The Bollinger Bands show a sideways trend weekly and bearish monthly. Dow Theory suggests a mildly bullish outlook on the weekly basis, but no trend on the monthly. In terms of performance, Bristol Myers Squibb has underperformed the S&P 500 across multiple periods, with a year-to-date return of -19.40% compared to the S&P 500's 16.30%, and a one-year return of -16.07% versus 19.89%. Overall, the current technical stance is mildly bearish, with mixed signals across different indicators....

Read More

Is Bristol Myers Squibb Co. technically bullish or bearish?

As of 31 October 2025, the technical trend for Bristol Myers Squibb Co. has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD is bearish. The daily moving averages are also mildly bearish, and the KST shows bearish signals on both weekly and monthly time frames. The Bollinger Bands are sideways weekly and mildly bearish monthly, and the Dow Theory indicates no trend weekly but mildly bearish monthly. Overall, the technical stance is mildly bearish with weak momentum. In terms of performance, Bristol Myers Squibb has underperformed the S&P 500 across multiple periods, with a year-to-date return of -18.64% compared to the S&P 500's 16.30%, and a 1-year return of -15.28% versus 19.89% for the index....

Read More

Is Bristol Myers Squibb Co. technically bullish or bearish?

As of 31 October 2025, the technical trend for Bristol Myers Squibb Co. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages and the overall bearish signals from the KST and Bollinger Bands on the monthly timeframe. The MACD indicates a mildly bullish trend on the weekly basis but remains bearish monthly, which adds to the mixed signals. The stock has underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -18.55% versus the S&P 500's 16.30%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
6.47%
EBIT Growth (5y)
23.31%
EBIT to Interest (avg)
5.76
Debt to EBITDA (avg)
1.96
Net Debt to Equity (avg)
2.19
Sales to Capital Employed (avg)
0.68
Tax Ratio
10.99%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
84.07%
ROCE (avg)
13.51%
ROE (avg)
33.03%
Valuation key factors
Factor
Value
P/E Ratio
15
Industry P/E
Price to Book Value
7.62
EV to EBIT
15.62
EV to EBITDA
9.01
EV to Capital Employed
3.08
EV to Sales
3.58
PEG Ratio
10.51
Dividend Yield
76.91%
ROCE (Latest)
19.69%
ROE (Latest)
49.65%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 247 Schemes (34.8%)

Foreign Institutions

Held by 593 Foreign Institutions (19.79%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 9.53% vs -9.24% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -46.67% vs 3,139.47% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "12,269.00",
          "val2": "11,201.00",
          "chgp": "9.53%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "5,146.00",
          "val2": "4,549.00",
          "chgp": "13.12%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "485.00",
          "val2": "494.00",
          "chgp": "-1.82%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-2,638.00",
          "val2": "-523.00",
          "chgp": "-404.40%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1,313.00",
          "val2": "2,462.00",
          "chgp": "-46.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "335.60%",
          "val2": "314.30%",
          "chgp": "2.13%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 7.32% vs -2.50% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -211.11% vs 26.71% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "48,300.00",
          "val2": "45,006.00",
          "chgp": "7.32%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "19,309.00",
          "val2": "18,283.00",
          "chgp": "5.61%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1,947.00",
          "val2": "1,166.00",
          "chgp": "66.98%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-18,154.00",
          "val2": "-1,056.00",
          "chgp": "-1,619.13%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-8,933.00",
          "val2": "8,040.00",
          "chgp": "-211.11%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "200.00%",
          "val2": "188.20%",
          "chgp": "1.18%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
12,269.00
11,201.00
9.53%
Operating Profit (PBDIT) excl Other Income
5,146.00
4,549.00
13.12%
Interest
485.00
494.00
-1.82%
Exceptional Items
-2,638.00
-523.00
-404.40%
Consolidate Net Profit
1,313.00
2,462.00
-46.67%
Operating Profit Margin (Excl OI)
335.60%
314.30%
2.13%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 9.53% vs -9.24% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -46.67% vs 3,139.47% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
48,300.00
45,006.00
7.32%
Operating Profit (PBDIT) excl Other Income
19,309.00
18,283.00
5.61%
Interest
1,947.00
1,166.00
66.98%
Exceptional Items
-18,154.00
-1,056.00
-1,619.13%
Consolidate Net Profit
-8,933.00
8,040.00
-211.11%
Operating Profit Margin (Excl OI)
200.00%
188.20%
1.18%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 7.32% vs -2.50% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -211.11% vs 26.71% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Bristol Myers Squibb Co. stock-summary
stock-summary
Bristol Myers Squibb Co.
Pharmaceuticals & Biotechnology
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. Its products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world. Its subsidiaries are Celgene Corp and MyoKardia, Inc.
Company Coordinates stock-summary
Company Details
430 E 29th St Fl 14 , NEW YORK NY : 10016-8367
stock-summary
Tel: 1 212 54640001 609 2527509
stock-summary
https://www.bms.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."